Navigation Links
Soligenix Reports Second Quarter 2010 Financial Results and Reviews Accomplishments

PRINCETON, N.J., Aug. 13 /PRNewswire-FirstCall/ -- Soligenix, Inc. (OTC Bulletin Board:

This press release contains forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes," "intends," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including orBec®, SGX201, RiVax™, and LPMTM, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec® for gastrointestinal GVHD include the risks that: the FDA's requirement that Soligenix conduct additional clinical trials to demonstrate the safety and efficacy of orBec® will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; Soligenix is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; orBec® may not gain market acceptance if it is eventually approved by the FDA; and others may develop technologies or products superior to orBec®. Factors affecting the development and use of SGX201 and LPMTM are similar to those affecting orBec®. These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Soligenix Announces Private Equity Financing of $5.16 Million With Its Partner Sigma-Tau and Other Institutional Investors
2. Soligenix Announces Grant of US Patent for the Treatment of Irritable Bowel Syndrome with Oral Beclomethasone Dipropionate
3. Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments
4. Soligenix Announces Completion of Patient Enrollment in Phase 2 Acute GVHD Prevention Clinical Trial
5. Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
6. Soligenix to Present at 12th Annual BIO CEO & Investor Conference
7. Soligenix Reports Third Quarter 2009 Financial Results
8. Soligenix to Present at 8th Annual BIO Investor Forum
9. Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
10. DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX
11. Oncothyreon reports second quarter 2010 financial results
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... ... of automation systems, material handling solutions and components, is opening its latest Parker ... State Street, the facility is Exotic’s second major expansion in Metropolitan Detroit in ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... educational opportunities for school age children in the areas of Science, Technology, Engineering ... sectors of the national economy, and the program aims to increase the number ...
(Date:10/12/2015)... , Oct.12, 2015  MiMedx Group, Inc. (NASDAQ: ... amniotic tissue and patent-protected processes to develop and market ... Orthopedic, Spine, Sports Medicine, Ophthalmic, and the Dental sectors ... had been filed against the Company has been dismissed ... , Chairman and CEO, stated, "As we suspected, this ...
(Date:10/12/2015)... 12 de octubre de 2015 El 8 ... a un récord en el congreso con su declaración ... la International Plasma Awareness Week (IPAW), que se celebrará ... patrocinada por la Plasma Protein Therapeutics Association ... , Aumentar la concienciación mundial acerca de ...
Breaking Biology Technology:
(Date:10/12/2015)... Research and Markets ( ) has announced the ... Market Shares, Strategies, and Forecasts, Worldwide, 2015-2021" to ... --> The study is designed to give a ... a selection from the mountains of data available of ... made by the most senior analysts. Commentary on every ...
(Date:10/12/2015)... , October 12, 2015 NXTD ) ... the growing mobile commerce market, reports on the recent SNS ... . --> NXTD ) ("NXT-ID" or the ... commerce market, reports on the recent SNS Future in Review ... --> NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ...
(Date:10/9/2015)... 2015 ... "Samsung Galaxy S6 Fingerprint Sensor - ... offering. --> ) has ... Galaxy S6 Fingerprint Sensor - Reverse Costing ... --> Research and Markets ( ...
Breaking Biology News(10 mins):